Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Long-term immunogenicity extension of altSonflex1-2-3 in African children
PACTR202510885048789Phase 2Not yet recruiting
- Sponsor
- GSK Vaccines Institute for Global Health
- Start
- Dec 2025
- Modality
- Vaccines & Immunotherapeutics
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of altSonflex1-2-3 in shigellosis, sponsored by GSK Vaccines Institute for Global Health. Primary endpoint: Anti-serotype specific Shigella LPS/O-antigen serum IgG. Planned start Dec 2025; status: not yet recruiting.
02
Drugs
altSonflex1-2-3
03
Conditions
shigellosis
Beyond the preview
Go deeper on PACTR202510885048789.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on PACTR202510885048789.